Director of the Access Strategy Group, Cell and Gene Therapy Catapult
Panos Kefalas is the Director of the Access Strategy Group at the Cell and Gene Therapy Catapult which provides strategic advice to address regulatory and reimbursement evidence generation needs for novel cell and gene therapies and maximize their adoption potential; the group includes non-clinical, clinical, regulatory, health economics and market access expertise. Over the previous 20 years Panos gained extensive experience in pharmaceutical pricing, reimbursement and health economics both from senior roles with major HEOR and market access consultancy firms (IMS Health plc / IOVIA, PriceSpective / ICON plc, United BioSource Corporation / Evidera plc) and from managing NICE guidance development. He obtained a PhD in Molecular Medicine from King’s College London, an MBA from Cranfield University and professional training in Health Economics from the University of Oxford and the Centre for Health Economics in York.
Stevenage Bioscience Catalyst30 November 2023